Clinically, although a Phase 2, open-label, single arm clinical trial has confirmed the safety and tolerability of pamrevlumab, a well-known monoclonal antibody to CTGF, in non-ambulatory participants with Duchenne muscular dystrophy patients (Clinical-Trials.gov: NCT02606136), further research is needed to evaluate the safety and efficacy of CTGF monoclonal antibody, like pamrevlumab, for IOP control in glaucoma patients. The gene discussed is CCN2; the disease is Duchenne muscular dystrophy.